Rafał Dankowski

Dr. Rafał Dankowski

2nd Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in JACC: Heart Failure
Verified
Journal Article
Closed access
MCMarco Canepa
Marco Canepa
CFCandida Fonseca
Candida Fonseca
OCOvidiu Chioncel
Ovidiu Chioncel
CLCécile Laroche
Cécile Laroche
MCMaria G. Crespo-Leiro
Maria G. Crespo-Leiro
HGH. Gunes
H. Gunes

11 June 2014 in Polish Heart Journal
Verified
Journal Article
Closed access
Rafał DankowskiRafał Dankowski
Rafał Dankowski
ABArtur Baszko
Artur Baszko
MSMichael Sutherland
Michael Sutherland
LFLudwik Firek
Ludwik Firek
PKPiotr Kałmucki
Piotr Kałmucki
TSTomasz Siminiak
Tomasz Siminiak
Structural heart disease, including valvular disease as well as congenital defects, causes important alterations in heart anatomy. As a result, individualised planning for both surgical and percutaneous procedures is crucial for procedural optimisation. Three dimensional (3D) rapid prototyping techniques are being utilised to aid operators in planning structural heart procedures. We intend to provide a description of 3D printing as a clinically applicable heart modelling technology for the planning of percutaneous structural heart procedures as well as to report our first clinical use of a 3D printed patient-specific heart model in preparation for a percutaneous mitral annuloplasty using the Mitralign percutaneous annuloplasty system. Retrospectively gated, contrast enhanced, multi-slice computed tomography (MSCT) scans were obtained. MSCT DICOM data was analysed using software that creates 3D surface files of the blood volume of specific regions of interest in the heart. The surface files are rendered using a software package that creates a solid model that can be printed using commercially available stereolithography machines. The technique of direct percutaneous mitral annuloplasty requires advancement of a guiding catheter through the aorta, into the left ventricle, and requires the positioning of the tip of the catheter between the papillary muscles in close proximity to the mitral annulus. The 3D heart model was used to create a procedural plan to optimise potential device implantation. The size of the deflectable guiding catheter was selected on the basis of the patient's heart model. Target locations for annulus crossing wires were evaluated pre-procedurally using the individual patient's 3D heart model. In addition, the ability to position the Bident Catheter at the appropriate locations under the mitral annulus as well as the manoeuvrability between the papillary muscles were analysed on the heart model, enabling safe completion of the procedure, which resulted in a significant reduction in mitral regurgitation. 3D printing is a helpful tool in individualised planning for percutaneous structural interventions. Future studies are warranted to assess its role in preparing for percutaneous and surgical heart procedures.

13 December 2013 in Polish Heart Journal
Verified
Journal Article
Closed access
TSTomasz Siminiak
Tomasz Siminiak
Rafał DankowskiRafał Dankowski
Rafał Dankowski
ABArtur Baszko
Artur Baszko
CLChristopher Lee
Christopher Lee
LFLudwik Firek
Ludwik Firek
AGAdam Groothuis
Adam Groothuis
Functional mitral regurgitation (FMR) is known to contribute to a poor prognosis in patients with heart failure (HF). Current guidelines do not recommend cardiac surgery in patients with FMR and impaired ejection fraction due to the high procedural risk. Percutaneous techniques aimed at mitral valve repair may constitute an alternative to currently used routine medical treatment. To provide a description of a novel percutaneous suture-based technique of direct mitral annuloplasty using the Mitralign Bident system, as well as report our first case successfully treated with this method. A deflectable guiding catheter is advanced via the femoral route across the aortic valve to the posterior wall of the ventricle. A nested deflectable catheter is advanced through the guide toward the mitral annulus that allows the advancement of an insulated radiofrequency wire to cross the annulus. The wire is directed across the annulus in a target area that is 2-5 mm from the base of the leaflet into the annulus, as assessed by real-time 3D transoesophageal echocardiography. After placement of the first wire, another wire is positioned using a duel lumen bident delivery catheter, which provides a predetermined separation between wires (i.e. 14, 17 or 21 mm). Each wire provides a guide rail for implantation of sutured pledget implants within the annulus. Two pairs of pledgets are implanted, one pair in each of the P1 and P3 scallop regions of the posterior mitral annulus. A dedicated plication lock device is used to provide a means for plication of the annulus within each pair of the pledgets, and to retain the plication by delivering a suture locking implant. The plications result in improved leaflet coaptation and a reduction of the regurgitant orifice area. A 60-year-old female with diagnosed dilated cardiomyopathy, concomitant FMR class III and congestive HF was successfully treated with the Mitralign Bident system. Two pairs of pledgets were implanted resulting in an improvement of transoesophageal echocardiographic parameters, including proximal isovelocity surface area radius (0.7 cm to 0.4 cm), effective regurgitant orfice area (0.3 cm² to 0.1 cm²) and mitral regurgitant volume (49 mL to 10 mL). Percutaneous mitral annuloplasty with the Mitralign Bident system is feasible. Future clinical trials are needed to assess its safety and efficacy.

14 April 2017 in Polish Heart Journal
Verified
Journal Article
Open access
PDF file
JZJoanna Zaprutko
Joanna Zaprutko
MMMichał Michalak
Michał Michalak
ANAnna Nowicka
Anna Nowicka
Rafał DankowskiRafał Dankowski
Rafał Dankowski
JDJaroslaw Drozdz
Jaroslaw Drozdz
ASAndrzej Szyszka
Andrzej Szyszka
Background: Heart failure (HF) is a chronic disease with poor prognosis, being the final stage of many cardiovascular conditions and often requiring hospitalisation. Aim: The aim of the study was to evaluate the effect of hospitalisation length on prognosis in patients with HF. Methods: Between February 2012 and January 2013, in 32 cardiology centres in Poland, 1126 HF patients were included in the EURObservational Research Programme on Heart Failure Registry. A total of 765 persons were hospitalised. A follow-up (FU) of 414 ± 121 days was conducted. Results: The median length of hospitalisation was seven days (interquartiles 25th–75th; 4–11), also for new onset (14.5% of patients) and chronic HF (seven days, 5–11 and 4–11, respectively). Patients who died during FU (16.5%) and those who survived were hospitalised for a median of eight days (6–12) and seven days (4–10), respectively (p < 0.001). Patients hospitalised for 8–21 and 22 or more days had an increased risk of death after discharge (hazard ratio [HR] 1.70; 95% confidence interval [CI] 1.16–2.49 and HR 2.20; 95% CI 1.04–4.67, respectively) than those hospitalised for up to seven days. Predictors of death in the FU period in multivariate analysis included age (1.02; 95% CI 1.01–1.04), history of chronic kidney disease (CKD) (HR 1.55; 95% CI 1.05–2.30), and New York Heart Association (NYHA) class III (HR 2.52; 95% CI 1.22–5.18) and IV (HR 4.77; 95% CI 2.32–9.82) at admission. Patients hospitalised for 22 or more days were more often male (77%), and with a history of CKD (34%). At admission they had lower systolic (118 ± 25 mm Hg) and diastolic (72 ± 12 mm Hg) blood pressure, higher NT-proBNP (9191 ± 8776 pg/mL), lower serum sodium level (137 ± 5 mmol/l), as well as lower ejection fraction before and during hospital stay (30 ± 12% and 34 ± 14%, respectively; p < 0.05 for all factors). Factors that influenced the length of hospital stay included history of CKD (p < 0.001), current malignancy (p = 0.026), and infection at admission (p < 0.001). Most of the admitted patients presented NYHA class III (45%). The poorer the NYHA class at admission, the longer the patient’s hospital stay (p < 0.001). 54% patients were re-admitted to the hospital during FU. Patients re-admitted and not re-admitted during the one-year FU had the same median duration of the index hospitalisation (seven days; 4–10 and 4–11, respectively; p = 0.957). Conclusions: Patients with HF hospitalised for 22 or more days, in comparison to patients hospitalised for less than eight days, had double the risk of death during FU. We believe that prolonged hospitalisation might be regarded as a marker of poor prognosis in patients with acute HF. Background: Heart failure (HF) is a chronic disease with poor prognosis, being the final stage of many cardiovascular conditions and often requiring hospitalisation. Aim: The aim of the study was to evaluate the effect of hospitalisation length on prognosis in patients with HF. Methods: Between February 2012 and January 2013, in 32 cardiology centres in Poland, 1126 HF patients were included in the EURObservational Research Programme on Heart Failure Registry. A total of 765 persons were hospitalised. A follow-up (FU) of 414 ± 121 days was conducted. Results: The median length of hospitalisation was seven days (interquartiles 25th–75th; 4–11), also for new onset (14.5% of patients) and chronic HF (seven days, 5–11 and 4–11, respectively). Patients who died during FU (16.5%) and those who survived were hospitalised for a median of eight days (6–12) and seven days (4–10), respectively (p < 0.001). Patients hospitalised for 8–21 and 22 or more days had an increased risk of death after discharge (hazard ratio [HR] 1.70; 95% confidence interval [CI] 1.16–2.49 and HR 2.20; 95% CI 1.04–4.67, respectively) than those hospitalised for up to seven days. Predictors of death in the FU period in multivariate analysis included age (1.02; 95% CI 1.01–1.04), history of chronic kidney disease (CKD) (HR 1.55; 95% CI 1.05–2.30), and New York Heart Association (NYHA) class III (HR 2.52; 95% CI 1.22–5.18) and IV (HR 4.77; 95% CI 2.32–9.82) at admission. Patients hospitalised for 22 or more days were more often male (77%), and with a history of CKD (34%). At admission they had lower systolic (118 ± 25 mm Hg) and diastolic (72 ± 12 mm Hg) blood pressure, higher NT-proBNP (9191 ± 8776 pg/mL), lower serum sodium level (137 ± 5 mmol/l), as well as lower ejection fraction before and during hospital stay (30 ± 12% and 34 ± 14%, respectively; p < 0.05 for all factors). Factors that influenced the length of hospital stay included history of CKD (p < 0.001), current malignancy (p = 0.026), and infection at admission (p < 0.001). Most of the admitted patients presented NYHA class III (45%). The poorer the NYHA class at admission, the longer the patient’s hospital stay (p < 0.001). 54% patients were re-admitted to the hospital during FU. Patients re-admitted and not re-admitted during the one-year FU had the same median duration of the index hospitalisation (seven days; 4–10 and 4–11, respectively; p = 0.957). Conclusions: Patients with HF hospitalised for 22 or more days, in comparison to patients hospitalised for less than eight days, had double the risk of death during FU. We believe that prolonged hospitalisation might be regarded as a marker of poor prognosis in patients with acute HF.

6 March 2015 in EP Europace
Verified
Journal Article
Closed access
PDF file
ABArtur Baszko
Artur Baszko
PKPiotr Kałmucki
Piotr Kałmucki
Rafał DankowskiRafał Dankowski
Rafał Dankowski
MŁMagdalena Łanocha
Magdalena Łanocha
TSTomasz Siminiak
Tomasz Siminiak
ASAndrzej Szyszka
Andrzej Szyszka
Aims Inferior vena cava (IVC) interruption is a rare anatomic variant where the azygos vein (AV) drains the blood from the IVC to the upper part of the right atrium via the superior vena cava. Here, we report balloon cryoablation of the pulmonary veins (PVs) via superior access in a patient with atrial fibrillation. Methods and results After the first failed ablation attempt due to IVC interruption, balloon cryoablation with a 28-mm Arctic Front Advance cryoballoon (Medtronic CryoCath LP, Quebec, Canada) via superior access was performed; it requires only a single transseptal puncture (TP), and the patient had optimal PV anatomy. Deflectable electrodes were inserted into the right ventricle and coronary sinus from the right femoral vein. The right internal jugular vein was accessed using an SL0 transseptal sheath and BRK needle. The TP was performed under transoesophageal echocardiographic guidance with a Safe Sept wire because the septum was stiff. All PVs were engaged: the left using an ablation catheter before balloon insertion and the inferior following a ‘push-up’ technique because of a leak above the veins. Cryothermal energy was delivered after checking for occlusion. The procedure lasted 210 min, fluoroscopy time was 78 min, and air-kerma dose was 194 mGy. During the 6-month follow-up, no episodes of atrial fibrillation were detected on several Holter recordings. Conclusions Successful PV isolation in patients with AV continuation of an interrupted IVC can be safely performed using superior access with balloon cryoablation, after several modifications of standard equipment.

1 January 2021 in Neuropsychiatria i Neuropsychologia
Verified
Journal Article
Closed access
Rafał DankowskiRafał Dankowski
Rafał Dankowski
WSWioletta Sacharczuk
Wioletta Sacharczuk
DDDominika Duszyńska
Dominika Duszyńska
WMWeronika Mikołajewska
Weronika Mikołajewska
ASAnna Szałek-Goralewska
Anna Szałek-Goralewska
DŁDorota Łojko
Dorota Łojko
Introduction To evaluate the presence and severity of anxiety and depressive symptoms in patients who recently recovered from coronavirus disease 2019 (COVID-19). Material and methods In this crosssectional observational study, patients who had recovered from COVID-19 were assessed between...